Minoryx Therapeutics is a clinical-stage biotech developing leriglitazone, a novel brain-penetrant selective PPARγ agonist, for X‑linked adrenoleukodystrophy (X‑ALD) and other CNS diseases. Its lead program, leriglitazone (MIN-102), showed significant clinical benefit in the ADVANCE Phase II/III trial in adult male AMN patients, reducing progression of cerebral lesions and myelopathy symptoms. The company is also running NEXUS, an open-label Phase II/III study in male pediatric patients with early-stage cerebral ALD. Minoryx intends to use the new funding to support the marketing authorization application (MAA) and launch preparations in the EU for adult male X‑ALD patients with AMN and to pursue approval in the US for the same indication. Proceeds will also fund continued development in pediatric cALD and label-expansion efforts into women affected by X‑ALD. The company is led by CEO Marc Martinell and is based in Mataró, Barcelona, Spain, with Belgian facilities. Minoryx Therapeutics is a clinical‑stage biotech focused on new therapies for rare central nervous system (CNS) disorders, with its lead asset leriglitazone (MIN‑102). Leriglitazone is a selective PPARγ agonist being evaluated in three advanced clinical trials: ADVANCE (phase II/III in adrenomyeloneuropathy, AMN), NEXUS (phase II in cerebral adrenoleukodystrophy, cALD) and FRAMES (phase II in Friedreich’s ataxia). The compound has demonstrated brain penetration, a favorable safety profile in phase 1, and preclinical proof‑of‑concept across models of mitochondrial dysfunction, neuroinflammation, demyelination and axonal degeneration. In October 2020 the European Investment Bank approved a €25M venture debt facility to support the development of leriglitazone, provided under the European Fund for Strategic Investments (FEIE). The financing will fund R&D activities targeting orphan genetic CNS diseases and is expected to create more than 50 jobs during implementation. Minoryx was founded in 2011, operates in Spain and Belgium, and to date has raised more than €60M from a consortium of international investors. Minoryx Therapeutics, based in Mataró, Barcelona, is a clinical-stage company focused on therapies for X‑ALD and other rare diseases. Its lead compound, MIN-102, is an orally bioavailable, selective PPAR gamma agonist with a profile suited to CNS-related diseases. MIN-102 is currently in a phase 2/3 clinical trial for adrenomyeloneuropathy (AMN), enrolling adult male patients in Europe and the US, with results expected in 2020. The company intends to use new proceeds to expand the list of indications for MIN-102 and to conduct a new clinical trial for a second orphan CNS indication. Founded in 2011 and led by co-founder and CEO Marc Martinell, Minoryx has raised a total of €50M to date. Khalid Islam serves as chairman of the board. Minoryx Therapeutics, based in Mataró, Barcelona, focuses on discovering new drugs for orphan diseases using its proprietary SEE-Tx platform. Its lead program, MIN-102, is a differentiated PPAR gamma agonist being advanced for multiple CNS indications. The company is exploring MIN-102 for clinical validation in X-ALD, a genetic, progressive neurodegenerative disease with no available pharmacological treatment. Minoryx is also developing a pipeline of non-competitive pharmacological chaperones identified via SEE-Tx. The company intends to use new funds to expand its team, particularly in R&D, and to progress MIN-102 into clinical development. The company is led by CEO and co-founder Marc Martinell. Minoryx focuses on developing therapies for congenital errors of metabolism and other rare or orphan diseases, including a lead program targeting adrenoleukodystrophy (ALD). The company was founded in 2011 and is based at Parc TecnoCampus Mataró‑Maresme. Its lead program is a first drug candidate for ALD; with the new funding the company plans to begin clinical trials. Minoryx closed a €1.6 million financing in early 2015 led by Caixa Capital Risc through the Caixa Innvierte BioMed II fund, with participation from the Swiss Sanfilippo Foundation; that operation also saw the exit of Inveready. The business targets indications for which there are often no approved treatments and is positioning its pipeline toward clinical development.

Total raised

$136M

Funding rounds

8

Latest round

Series C

Latest activity

May 2022